Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm.
about
Gas-filled phospholipid nanoparticles conjugated with gadolinium play a role as a potential theragnostics for MR-guided HIFU ablationCorrelation between in vitro and in vivo activities of GM 237354, a new sordarin derivative, against Candida albicans in an in vitro pharmacokinetic-pharmacodynamic model and influence of protein bindingA new approach to predicting human hepatic clearance of CYP3A4 substrates using monkey pharmacokinetic data.Interspecies scaling: is a priori knowledge of cytochrome p450 isozymes involved in drug metabolism helpful in prediction of clearance in humans from animal data?Animal pharmacokinetics and interspecies scaling of sordarin derivatives following intravenous administration.Prediction of human pharmacokinetics of panipenem-betamipron, a new carbapenem, from animal data.Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.Prediction of clinical pharmacokinetic parameters of linezolid using animal data by allometric scaling: applicability for the development of novel oxazolidinones.Recent advances in pharmacokinetic extrapolation from preclinical data to humans.Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: volume of distribution at steady state.Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenemPrediction of human oral plasma concentration-time profiles using preclinical data: comparative evaluation of prediction approaches in early pharmaceutical discovery.Antibiotic administration in the drinking water of micePrediction of drug concentration-time data in humans from animals: a comparison of three methods.Scaling for size: some implications for paediatric anaesthesia dosing.Scaling basic toxicokinetic parameters from rat to man.Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.Predicting pediatric age-matched weight and body mass indexForecasting cephalosporin and monobactam antibiotic half-lives in humans from data collected in laboratory animals.Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model.Pharmacokinetic studies and renal dehydropeptidase stability of the new beta-lactamase inhibitor BRL 42715 in animalsPhysiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.Prediction of pharmacokinetics and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach: A case study of caffeine and ciprofloxacin.Interspecies scaling of therapeutic monoclonal antibodies: initial look.Prediction of exposure-response relationships to support first-in-human study design.Prediction of drug clearance in children 3 months and younger: an allometric approach.Approaches for predicting human pharmacokinetics using interspecies pharmacokinetic scaling.Merging systems biology with pharmacodynamics.Interspecies scaling and comparisons in drug development and toxicokinetics.Physiological pharmacokinetic modelling.Prediction of drug concentration-time profiles of therapeutic proteins in humans from animals.Contrasting toxicokinetic evaluations and interspecies pharmacokinetic scaling approaches for small molecules and biologics: applicability to biosimilar development.Allometric scaling and prediction of concentration-time profiles of coagulation factors in humans from animals.Designing first-in-human dose of coagulation factors: application of pharmacokinetic allometric scaling.Prediction of drug clearance in children: an evaluation of the predictive performance of several models.Prediction of drug clearance in children: a review of different methodologies.Prediction of Antimalarial Drug Clearance in Children: A Comparison of Three Different Interspecies Scaling Methods.Prediction of Clearance, Volume of distribution, and Half-life of Drugs in Extremely Low to Low Birth Weight Neonates: An Allometric Approach.Physiologic pharmacokinetic modeling.
P2860
Q27305262-749280D9-E513-4FB5-93A3-B4711E8CB020Q28353204-A0424F23-2980-46C4-BCB9-CB06500B77CDQ30577525-1FA75E06-97FB-46F9-868F-4211A1350C91Q30656662-6E3216D5-7BA3-4C7E-9094-D9C54BD8FE3FQ30660609-7B50AE35-5F99-41EC-9A2E-3462EAF74CB4Q30868180-70D1F4B3-8642-4F00-BE3D-998C0ADC8CD6Q30930928-4EF5099C-1CBC-47AF-88AE-0312FD4B0CB4Q30947691-D6E5F2EC-985B-4D36-BAEB-95B73FB4DCC7Q31049599-36D8A851-8E03-4C6E-BD50-028DD15629C6Q33188075-BE156D87-E83E-49BA-8C4F-4D4C32B12880Q33723852-94D3F85C-00D1-4F2B-B921-6980D08F84CAQ33938036-00AF9BAF-F863-4941-9E29-25C621692775Q33955715-4817DDB1-11CE-4F80-A7E4-5A30545C7F8AQ34027068-510AA64E-8128-4B51-9898-67D2345CF729Q34168842-80A961EA-1656-4E06-A008-A21D02456DACQ34570931-8B58FFA8-478F-41CB-A133-A9E5962A4263Q34635619-84DDECDC-0EE3-4075-AD0D-426E113ED86EQ35027930-C07404CD-2DF3-417E-8530-A9C7F691F7F5Q35318223-DEAFCEAC-9505-412F-9F03-E6D6CE91AEB3Q35645087-8B9BCD87-3E39-4F86-BBF7-AC5659EE213CQ36087076-AA3D7A3C-7C36-465E-A9C9-0B891BE64C1FQ36754774-C7C05EF5-0E70-438F-807E-93570C96D012Q37008900-7702FF88-2A80-4514-95EE-8269A4E556E9Q37559546-2BF5C7DD-E160-4F8D-B8D1-8133E3897090Q37616947-09EC7276-34AC-4D8F-80DC-3441EC307279Q37802266-34A2F9A4-252E-4C9B-9E99-105C297D8367Q37854677-611F582D-5490-4133-AD70-B575555619D9Q37964570-84AE20C9-D037-4EAE-B607-925AFC0516ADQ37996185-7D9BD220-7C9B-4B31-8821-02B3A6BE9763Q38023215-659B6125-C86C-4C77-B50E-D932C2123CCBQ38023217-029722F5-F96C-4DCB-8EAE-A172CAAA43F5Q38029383-D3F4CB52-47A1-4423-A36A-1EA61894D311Q38067822-006DE288-D25E-44C2-8F16-872976A5A8B0Q38079864-BEAF9A27-D8B4-4D56-9993-2D42907CE598Q38121644-B55723E6-A654-4755-8AE8-3390352FBDC8Q38256006-288929EC-3FEA-4753-B7D2-5AAD2485FEF3Q38367747-0AB4BF25-97CA-4666-9613-FB3C18E8EBFBQ38627882-931758A6-73C7-4F79-A8D8-4D83C6646DE3Q38937378-9EAADF94-58FF-4AAA-8CB7-D4300F56A3A7Q39555387-0E6555BB-3147-44D6-91F3-3A1D9E0F3337
P2860
Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
1984年论文
@zh
1984年论文
@zh-cn
name
Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm.
@en
type
label
Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm.
@en
prefLabel
Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm.
@en
P2860
P1476
Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm.
@en
P2093
Boxenbaum H
P2860
P304
P356
10.3109/03602538409033558
P407
P577
1984-01-01T00:00:00Z